Clinical Trial Update: Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial comparing MW05 with PEG-rhG-CSF in breast cancer indicates completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MW05
• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Breast Cancer Female | Phase 2, Phase 3 | Status: COMPLETED